Address: 11 Grand Avenue, Camellia, NSW 2142,Australia
Tel: (02) 8844 2000
Australian Pharmaceutical Industries Limited (API) has developed into one of Australia’s leading beauty and health retail companies. API was founded in 1910 and became one of Australia’s leading pharmaceutical distributors. Changes within the pharmacy industry propelled API to focus on the needs of consumers and patients thereby developing a retail footprint and retail services that provide growth opportunities for the company today.
API is one of the leading service providers to the pharmacy industry in Australia and today has a relationship with more than 4000 independent pharmacies. The services include wholesale product delivery, retail services, marketing programs and business advisory services. API also owns and operates the Priceline retail store brand that is a leading health and beauty brand in Australia. The company has product manufacturing capabilities and it is a niche player in over-the-counter pharmaceuticals and toiletries, which supply the Australian and New Zealand markets.
The company underwent some landmark changes under your leadership, changing the balance between different pillars of the business – retail, wholesale product delivery, marketing programs. Would you begin by outlining…
Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes…
Shawview Consulting’s Brendan Shaw looks back on a sombre United Nations High Level Meeting on Universal Health Coverage in New York last month, as stakeholders reflected on the long road…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises…
Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research…
Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the…
Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped…
Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how…
In conversation in the November issue of DIA’s Global Forum magazine, Australian Pharmaceutical medical and scientific Professionals Association (APPA) Past President David Grolman highlights the contributions that Australia is already…
Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life…
See our Cookie Privacy Policy Here
